Quince Therapeutics, Inc. (NASDAQ:QNCX) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of series C non-voting convertible preferred stock and warrants Closed: US$115M raised · warrants that could bring up to an additional $83 million upon exercise (including… | Aug 14, 2026 |
| Private placement of shares of common stock (or pre-funded warrants) and accompanying common warrants Closed: US$11.5M raised · US$1.325 a share · Warrants at US$1.2 for 60 months · Citizens Capital Markets +2 Dealers: Citizens Capital Markets (lead), Maxim Group LLC, Brookline Capital Markets Buyers: Nantahala Capital (led the private placement); ADAR1 Capital Management; Quince senior management Insiders: Members of Quince's senior management participated Use of proceeds: Working capital and general corporate purposes, including Phase 3 NEAT trial enrollment in A-T, R&D, G&A and capital expenditures | Jun 18, 2025 |